Inavolisib + Atezolizumab + Pembrolizumab
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PIK3CA-Mutated Cancers
Conditions
PIK3CA-Mutated Cancers
Trial Timeline
Dec 11, 2023 → Sep 28, 2028
NCT ID
NCT06496568About Inavolisib + Atezolizumab + Pembrolizumab
Inavolisib + Atezolizumab + Pembrolizumab is a phase 1 stage product being developed by Roche for PIK3CA-Mutated Cancers. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06496568. Target conditions include PIK3CA-Mutated Cancers.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06496568 | Phase 1 | Recruiting |